Compare · NSPR vs WST
NSPR vs WST
Side-by-side comparison of InspireMD Inc. (NSPR) and West Pharmaceutical Services Inc. (WST): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NSPR and WST operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- WST is the larger of the two at $26.45B, about 1306.1x NSPR ($20.3M).
- Over the past year, NSPR is down 68.5% and WST is up 49.7% - WST leads by 118.2 points.
- WST has been more active in the news (6 items in the past 4 weeks vs 5 for NSPR).
- WST has more recent analyst coverage (20 ratings vs 1 for NSPR).
- Company
- InspireMD Inc.
- West Pharmaceutical Services Inc.
- Price
- $0.76+0.75%
- $375.54+1.06%
- Market cap
- $20.3M
- $26.45B
- 1M return
- -13.22%
- +6.30%
- 1Y return
- -68.54%
- +49.67%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- AMEX
- NYSE
- IPO
- News (4w)
- 5
- 6
- Recent ratings
- 1
- 20
InspireMD Inc.
InspireMD, Inc., a medical device company, focuses on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia. The company offers CGuard carotid embolic prevention system for use in carotid artery applications; and MGuard Prime embolic protection systems for use in patients with acute coronary syndromes, notably acute myocardial infarction, and saphenous vein graft coronary interventions. It is also developing NGuard, a neurovascular flow diverter that diverts blood flow away from cerebral aneurysms and seals the aneurysms. The company sells its products through local distributors. InspireMD, Inc. was founded in 2005 and is headquartered in Tel Aviv, Israel.
West Pharmaceutical Services Inc.
West Pharmaceutical Services, Inc. designs and produces containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging components. It also provides drug containment solutions, including Crystal Zenith, a cyclic olefin polymer in the form of vials, syringes, and cartridges; and self-injection devices, as well as a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. It serves pharmaceutical, diagnostic, and medical device companies. The company distributes its products through its sales force and distribution network, as well as contract sales agents and regional distributors. West Pharmaceutical Services, Inc. was incorporated in 1923 and is headquartered in Exton, Pennsylvania.
Latest NSPR
- SEC Form 4 filed by Director Roubin Gary S
- SEC Form 4 filed by Director Berman Michael
- SEC Form 4 filed by Director Stuka Paul
- InspireMD Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Financial Statements and Exhibits
- InspireMD to Participate in Upcoming H.C. Wainwright 28th Annual Global Investment Conference
- InspireMD Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- SEC Form 10-Q filed by InspireMD Inc.
- InspireMD to Announce Second Quarter 2026 Financial Results
- InspireMD Appoints Carotid Intervention Commercial Leader Kathleen Kennedy as Senior Vice President of Global Sales and Marketing
- InspireMD Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
Latest WST
- West Pharm upgraded by Morgan Stanley with a new price target
- Sr. VP & Chief HR Officer Favorite Annette F exercised 7,524 shares at a strike of $89.64 and sold $2,671,260 worth of shares (7,524 units at $355.03) (SEC Form 4)
- Sr. VP & Chief HR Officer Favorite Annette F exercised 8,135 shares at a strike of $85.37 and sold $2,772,489 worth of shares (8,135 units at $340.81) (SEC Form 4)
- SEC Form 4 filed by President and CEO Lagarde Michel
- New insider Lagarde Michel claimed ownership of 7,850 shares (SEC Form 3)
- UBS resumed coverage on West Pharm with a new price target
- West to Participate in Upcoming Investor Conferences
- SVP & Chief Financial Officer Mcmahon Robert W. converted options into 7,149 shares and covered exercise/tax liability with 3,109 shares, increasing direct ownership by 136% to 7,021 units (SEC Form 4)
- SEC Form 10-Q filed by West Pharmaceutical Services Inc.
- West Pharmaceutical Services Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits